Affiliation: Tufts Medical Center
- [Alcohol septal ablation and hypertrophic cardiomyopathy]Carey Kimmelstiel
Cardiac Catheterization Laboratory, Tufts Medical Center, Massachusetts 02111, USA
Zhonghua Xin Xue Guan Bing Za Zhi 37:1074-7. 2009..However, for a variety of clinical and logistical factors, such a trial is unlikely to ever be performed. For the foreseeable future, patient-specific therapy will depend on local expertise, patient comorbidities and preferences...
- Restrictions on interactions between doctors and industry could ultimately hurt patientsCarey Kimmelstiel
Cardiac Catheterization Laboratory and Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
J Vasc Surg 54:12S-4S. 2011..The following article reviews the effects of legislation on medical innovation as well as the impact on continuing medical education...
- Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducinPing Zhang
Hemostasis and Thrombosis Laboratory, Tufts Medical Center, Box 7510, 750 Washington St, Boston, MA 02111, USA
Circulation 126:83-91. 2012..The thrombin receptor, PAR1, has recently emerged as a promising new target for therapeutic intervention in patients with acute coronary syndromes...
- Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closureRavikiran Korabathina
Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
Catheter Cardiovasc Interv 80:498-502. 2012..We discuss risk factors that may have contributed to device thrombosis and raise concerns regarding the lack of a dedicated PFO closure device for clinical use in the United States...
- Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary interventionCarey Kimmelstiel
The Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
Circ Cardiovasc Interv 4:171-9. 2011..We tested the hypothesis that bivalirudin acts as an antiplatelet agent in PCI patients by preventing activation of PARs on the platelet surface...